Sean P. Nolan - 12 Jan 2026 Form 4 Insider Report for Taysha Gene Therapies, Inc. (TSHA)

Reporting relationship: Chief Executive Officer, Director
Issuer ticker: TSHA
Reported as of: 12 Jan 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 14 Jan 2026, 16:45:09 UTC
Prior SEC filing: 17 Feb 2026
Next SEC filing: 27 Jan 2026
Source filing: View source filing
Reporting owner signature: /s/ Kamran Alam, Attorney-in-Fact

Key filing fact

Sean P. Nolan filed Form 4 for Taysha Gene Therapies, Inc. (TSHA) on 14 Jan 2026.

Key facts

This page summarizes Sean P. Nolan's Form 4 filing for Taysha Gene Therapies, Inc. (TSHA).
2 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 14 Jan 2026, 16:45.

Change

Previous filing in this sequence was filed on 17 Feb 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001569926 Primary reporting owner

Nolan Sean P.

Relationship: Chief Executive Officer, Director
Address: C/O TAYSHA GENE THERAPIES, INC., 3000 PEGASUS PARK DRIVE, SUITE 1430, DALLAS
Signature: /s/ Kamran Alam, Attorney-in-Fact
Signature date: 14 Jan 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

TSHA transaction

Common Stock

Award

Transaction value: $0
Shares: +1,008,000
Change %: +48%
Price: $0.000000
Shares after: 3,086,358
Date: 12 Jan 2026
Ownership: Direct
Footnotes: F1

TSHA holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 1,535,545
Date: 12 Jan 2026
Ownership: See footnote
Footnotes: F2

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

TSHA transaction Derivative

Employee Stock Option (right to buy)

Award

Transaction value: $0
Shares: +648,000
Change %
Price: $0.000000
Shares after: 648,000
Date: 12 Jan 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 648,000
Exercise price: $4.86
Footnotes: F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 3 footnotes

Footnote F1

Represents a restricted stock unit ("RSU") award. The RSUs will vest in four equal annual installments beginning on January 12, 2027, subject to the Reporting Person's continuous service through each applicable vesting date.

Footnote F2

The securities are held by Nolan Capital, LLC (the "LLC"). The Reporting Person is the President of the LLC and has shared voting and investment power with respect to the shares held by the LLC.

Footnote F3

25% of the total number of shares underlying the option shall vest and become exercisable on January 12, 2027 and the remainder shall vest and become exercisable in 36 equal monthly installments thereafter, subject to the Reporting Person's continuous service through each applicable vesting date.